Multiple Myeloma – Geographic Focus: China – DIA: China In-Depth – Multiple Myeloma
China’s multiple myeloma therapy market is evolving rapidly, driven by an increasing disease burden and advances in treatment options. Current therapies in China largely mirror global standards; proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies (MAbs) form the backbone of treatment. Recent approvals of BCMA CAR T-cell therapies (CARsgen’s Saikaize, IASO’s Fukesu), BCMA x CD3 bispecific T-cell engagers (Johnson & Johnson Innovative Medicine’s Tecvayli), anti-CD38 MAbs (Sanofi’s Sarclisa), and TRAIL agonists (Wuhan Hiteck’s aponermin) are reshaping the treatment landscape, particularly for relapsed / refractory disease. Late-phase therapies (e.g., Johnson & Johnson Innovative Medicine’s talquetamab, Pfizer’s elranatamab) will further diversify treatment options upon approval. This report analyzes how clinical and nonclinical factors—price dynamics, inclusion in China’s National Reimbursement Drug List (NRDL), and the entry of generics or biosimilars—will influence the launch and uptake of new and existing multiple myeloma therapies during the forecast period.
QUESTIONS ANSWERED
- How large is China’s drug-treatable multiple myeloma population?
- Which are the most commercially relevant drugs in China’s multiple myeloma market?
- What are interviewed experts’ insights into current treatments? What are the key unmet needs in the management of multiple myeloma in China?
- What are the key market access considerations, and how will they impact the uptake of emerging therapies for multiple myeloma in China?
- What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy in China.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.
- Gauge the commercial outlook and impact of key market events.
Release date
October 2025
Geographies
China
Primary research
Qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 hematologist-oncologists in China
Epidemiology
Diagnosed incidence of multiple myeloma in urban versus rural China, clinically relevant and market-relevant drug-treatable populations
Forecast
10-year, annualized, drug-level sales and patient share of key multiple myeloma therapies through 2034, based on primary and secondary market research to formulate bottom-up assumptions
Drug treatments
Coverage of key current and late-phase emerging therapies
Custom drug modeler
Integrated tool to input customized forecast assumptions (e.g., launch date, price)
Table of contents
- Multiple Myeloma - Geographic Focus: China - DIA: China In-Depth - Multiple Myeloma
- Executive Summary
- Key Updates
- Disease Context
- Epidemiology
- Current Treatment
- Market Access
- Emerging Therapies
- Market Forecast
- Appendix
- Abbreviations
- Epidemiology methodology
- Epidemiology methodology: newly diagnosed incident cases of multiple myeloma
- Epidemiology methodology: diagnosed incident cases of multiple myeloma by ISS stage distribution
- Epidemiology methodology: diagnosed incident cases of multiple myeloma by symptoms
- Epidemiology methodology: diagnosed prevalent cases of multiple myeloma
- Epidemiology methodology: diagnosed asymptomatic multiple myeloma progression to symptomatic multiple myeloma
- Epidemiology methodology: drug-treatable populations
- Epidemiology methodology: drug-treated populations
- Bibliography
- Primary market research methodology
- China Biopharma Background
- Executive Summary
